Navigation Links
Some antipsychotic drugs may be missing their mark
Date:12/31/2007

COLUMBUS, Ohio Drugs that treat depression, schizophrenia and other psychotic conditions and that target a particular protein on brain cells might not be triggering the most appropriate response in those cells, new research suggests.

The study by researchers at The Ohio State University Medical Center examined the serotonin 2A receptor, a protein on brain cells sensitive to the neurotransmitter serotonin.

This study examined the early chemical events that happen inside neurons when the 2A receptor is stimulated by serotonin and by a synthetic hallucinogenic agent that is thought to mimic serotonin.

The findings, published online in the early edition of the Proceedings of the National Academy of Sciences with an accompanying editorial, show that although both compounds combine with and activate this receptor, they trigger different chemical pathways inside the neuron.

Researchers say that the work could have important implications for the development of drugs that affect the serotonin 2A receptor, a key target in the treatment of several important mental disorders.

This new insight into how serotonin and a hallucinogenic drug affect this serotonin receptor could lead to changes in how new drugs are screened and developed for depression, schizophrenia and other neuropsychiatric disorders, says study leader Laura M. Bohn, an associate professor of pharmacology and psychiatry.

Currently, it is thought that when serotonin binds with the receptor, it sends a signal that activates molecules inside the cell called G proteins.

This study shows, however, that the receptor responds to serotonin by also activating a protein called beta-arrestin inside the cell. The synthetic hallucinogen, on the other hand, causes the receptor to activate only the G proteins. The hallucinogen does not seem to use beta-arrestins to cause its effects.

For this study, Bohn and her colleagues used laboratory-grown cells and a strain of mice that lacked beta
'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Antidepressant as Good as Antipsychotics for Dementia
3. New review suggests caution on drugs to raise good cholesterol
4. Can cancer drugs combine forces?
5. Study provides hope that some transplant patients could live free of antirejection drugs
6. Study provides hope that some transplant patients could live free of anti-rejection drugs
7. RA Drugs Linked to Slight Skin Cancer Risk
8. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
9. Rock N Roll: Sex, Drugs and an Early Exit
10. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair 28R 29 System for Severe 5807 1Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair 28R 29 System for Severe 5807 2Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair 28R 29 System for Severe 5807 3Experience the Future of Assistive Technology at Abilities Expo on November 6 8 2009 60288 1Experience the Future of Assistive Technology at Abilities Expo on November 6 8 2009 60288 2Nuvo announces 2009 third quarter financial results 60283 1Nuvo announces 2009 third quarter financial results 60283 2Nuvo announces 2009 third quarter financial results 60283 3Nuvo announces 2009 third quarter financial results 60283 4Nuvo announces 2009 third quarter financial results 60283 5Nuvo announces 2009 third quarter financial results 60283 6Nuvo announces 2009 third quarter financial results 60283 7Nuvo announces 2009 third quarter financial results 60283 8Nuvo announces 2009 third quarter financial results 60283 9Nuvo announces 2009 third quarter financial results 60283 10Nuvo announces 2009 third quarter financial results 60283 11Nuvo announces 2009 third quarter financial results 60283 12